Lanean...
Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study
BACKGROUND: Denosumab inhibits the receptor activator of nuclear factor κB (RANK) pathway and is used to treat osteoporosis. Emerging evidence suggests RANK-blockade may play a role in mammary tumourigenesis. Thus, we undertook a population-based study of denosumab use and breast cancer risk in a la...
Gorde:
| Argitaratua izan da: | Br J Cancer |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Publishing Group UK
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6265331/ https://ncbi.nlm.nih.gov/pubmed/30420611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0225-4 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|